Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Merck Serono Aims to Become Leading Company in Oncology: Dr Wein
May 3, 2010
- Chuikyo Members Call For Penalties for Fraudulent Practice
May 3, 2010
- JPMA Removes All MTPC Representatives from Executive Positions
May 3, 2010
- Japan Should Accept More Overseas Clinical Data: Mr Dunoyer
May 3, 2010
- Astellas Launches Prograf in India
May 3, 2010
- Positive Efficacy Data Obtained for MDV3100 in PI, PII: Astellas, Medivation
May 3, 2010
- Eisai Licenses Cinitapride from Almirall in China
May 3, 2010
- Lawmakers to Include Lifting of Ban on Online Sales of Drugs in DPJ Manifesto
May 3, 2010
- Sanofi-aventis Licenses New Diabetes Treatment from CureDM Sign
May 3, 2010
- No Call for Lifting of Ban on Kongo Shinryo from DPJ Lawmakers
May 3, 2010
- Kowa, Nitto Denko to Codevelop Transdermal Donepezil Patches
May 3, 2010
- Sato: Patch Test Tape for Allergic Skin Diseases
May 3, 2010
- Nippon Kayaku, Teva-Kowa to Develop G-CSF Biosimilar
May 3, 2010
- Medipolis Completes Cancer Radiotherapy Center in Kagoshima
May 3, 2010
- Biosimilar for EPO Priced at 77% of the Original Drug
May 3, 2010
- Astellas' VESIcare Website Contains “Unsubstantiated Superiority Claims” FDA
May 3, 2010
- Fentos Tape Approved in Japan: Hisamitsu, Kyowa Kirin
May 3, 2010
- Sanofi-aventis Aims at Double-Digit Growth Rate for 4 Years in a Row
May 3, 2010
- Biomedical Cluster Kansai Changes Its Operation Systems
April 26, 2010
- Only 12.6% of the Elderly Aware of Pneumococcal Vaccines
April 26, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…